---
title: "Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292885553.md"
description: "Wells Fargo analyst Yanan Zhu maintains a Buy rating on Atrium Therapeutics (RNA) with a $25 price target, despite shares closing at $12.30. The consensus remains Strong Buy with an average target of $25. Additionally, TipRanks launched the RANK ETF on NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies."
datetime: "2026-07-16T09:45:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292885553.md)
  - [en](https://longbridge.com/en/news/292885553.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292885553.md)
generator: "portal-rs"
---

# Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Atrium Therapeutics, Inc., with a price target of $25.00. The company’s shares closed yesterday at $12.30.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Zhu is a 5-star analyst with an average return of 16.0% and a 39.02% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, BeOne Medicines, and enGene Holdings.

Currently, the analyst consensus on Atrium Therapeutics, Inc. is a Strong Buy with an average price target of $25.00.

### Related Stocks

- [RNA.US](https://longbridge.com/en/quote/RNA.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [ENGN.US](https://longbridge.com/en/quote/ENGN.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)
- [ENGNW.US](https://longbridge.com/en/quote/ENGNW.US.md)

## Related News & Research

- [RNA: Advancing RNA therapies for rare cardiac diseases, with phase I/II data expected next year](https://longbridge.com/en/news/298330229.md)
- [FOCUS-Novartis investors turn spotlight on M&A after trial setbacks](https://longbridge.com/en/news/298681304.md)
- [PTCT: SEPHIENCE's global launch and pipeline advances set the stage for sustained growth and profitability](https://longbridge.com/en/news/298742897.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)
- [Ginkgo Bioworks joins Waterfall Scientific-led ARPA-H consortium to build autonomous RNA drug manufacturing system](https://longbridge.com/en/news/298590935.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**